台灣臨床試驗主持人資料庫|TPIDB

2017-07-01 - 2020-03-31

Phase II

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

Condition/Disease

Metastatic Triple Negative Breast Cancer
Test Drug

Olaparib (AZD2281), AZD6738 and AZD1775

Participate Sites
10Sites

Terminated9Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of General Internal Medicine

陳訓徹

Linkou Chang Gung Medical Foundation

2018-04-25 - 2023-07-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Condition/Disease

Systemic Lupus Erythematosus
Test Drug

Ustekinumab (STELARA)

Participate Sites
10Sites

Terminated8Sites

張棋楨

Taipei Medical University Hospital

羅淑芬

Linkou Chang Gung Medical Foundation

2018-02-01 - 2020-05-30

Phase III

A 12-week double-blind, randomized, multi-center study comparing the efficacy and safety of once monthly subcutaneous AMG 334 against placebo in adult episodic migraine patients (EMPOwER)

Condition/Disease

Episodic Migraine
Test Drug

AMG334

Participate Sites
9Sites

Terminated8Sites

Study ended1Sites

林剛旭

China Medical University Hospital

羅榮昇

Linkou Chang Gung Medical Foundation

2016-01-01 - 2019-12-31

Phase I

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

Condition/Disease

ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)
Test Drug

LDK378

Participate Sites
6Sites

Terminated5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

2016-02-22 - 2022-12-22

Phase II

A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

Condition/Disease

Non-small Cell Lung Cancer
Test Drug

INC280

Participate Sites
6Sites

Recruiting5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

張文震

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-02-28 - 2023-04-30

Phase II

A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Condition/Disease

Breast cancer
Test Drug

KISQALI

Participate Sites
9Sites

Recruiting8Sites

劉良智

China Medical University Hospital-Taipei

未分科

陳訓徹

Linkou Chang Gung Medical Foundation

2015-11-01 - 2017-10-31

Phase III

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

Condition/Disease

Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations
Test Drug

ASP8273

Participate Sites
9Sites

Terminated9Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-05-01 - 2023-10-30

Phase III

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

Condition/Disease

NSCLC
Test Drug

Nivolumab (BMS-936558),Ipilimumab (BMS-734016)

Participate Sites
16Sites

Terminated14Sites

黃煦晴

Taipei Veterans General Hospital

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2015-07-01 - 2023-10-27

Phase III

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Condition/Disease

Renal Cell Carcinoma
Test Drug

Nivolumab (BMS-936558)

Participate Sites
3Sites

Terminated3Sites

黃逸修

Taipei Veterans General Hospital

Division of Hematology & Oncology

張文震

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-04-01 - 2018-12-04

Phase I

Phase I Study of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Condition/Disease

Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Test Drug

NC-6004

Participate Sites
3Sites

Terminated3Sites

楊慕華

Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

Search Result

List